Want to join the conversation?
$REGN will be starting a 10,000 patient long-term treatment phase 3 clinical study of Fasinumab in 1H16. The company anticipates reporting data from a 16-week study in osteoarthritis pain in 1H16. In the early-stage pipeline, $REGN will share data from phase 1 and 2 studies of Evinacumab, antibody ANGPTL3 for dyslipidemia in 1H16.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.